Drug Approval | February 19, 2022
US FDA to review Amylyx new drug application for AMX0035
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Recall does not include any metabolic deficiency nutrition formulas
With ValGenesis VLMS, change control driven validation activities are reduced from weeks to mere hours, and the company gains faster access to detailed metrics that help reduce costs and cycle time
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Subscribe To Our Newsletter & Stay Updated
